TELUS Health Annual Conference 2024: Drug trends and healthcare transformations
Diabetes, depression, attention deficit hyperactivity disorder (ADHD) and cystic fibrosis are among...
Drug trends
Insurers and benefits administrators
Event and Webinar
Report
Get your copy: TELUS Health's 2024 Drug Data Trends & National Benchmarks report
For 16 years and counting, drugs for diabetes and depression have ranked in the top-five categories...
Report
What private plans need to know about Canada’s pipeline in 2024
In its 2024 Drug Pipeline report, TELUS Health draws attention to 12 new drugs due to their...
Report
2023 Category Watch: A closer look at disruption
TELUS Health’s 2023 Category Watch closely examines disruption in the drug categories of diabetes,...
Report
Your copy awaits: the 2023 Drug Data Trends & National Benchmarks report
At a high level, growth in spending by private drug plans was moderate for the third consecutive...
Event and Webinar
TELUS Health conference 2023: What you need to know about drug data trends
The key drivers of change in spending by private drug plans in 2022 can be boiled down to two...
Article
Everything that’s happening with biosimilars in Canada
The slow but steady adoption of biosimilars is big news. With provinces increasingly making the...
Article
How can pharmacogenetics help control employee benefit costs?
Pharmacogenetics (also known as pharmacogenomics) is one of the most exciting frontiers of medical...
Article
What private plans can expect in 2023 from Canada’s drug pipeline
Developments in the diabetes category—the second largest category by eligible amount in 2022—will...
Article
Medication adherence: how to help employees stay on track and save your bottom line
How confident are you that your employees are taking the prescribed medications your plan pays for?...
Article
5 levers to slow the rise of pharmacy benefits costs
It’s no secret that drug costs are on the rise. In 2021, compared to 2020, plans saw a 5.0% rise in...
Event and Webinar
What you need to know about drug data trends in 2022
For the second year in a row, the pandemic has resulted in fewer plan members making claims for...
Event and Webinar
From adherence to delayed diagnoses, what you need to know about medication use
Would it be better for patients to take more of a medication that may end up costing private drug...
Report
2022 category watch: Impact of the pandemic
TELUS Health’s 2022 Category Watch examines the impact of the COVID-19 pandemic on drug utilization...
Article
What new drugs are poised to have the biggest impact on plan costs?
The TELUS Health 2022 Drug Pipeline report looks at approved and likely soon-to-be-approved...
Article
The private payer’s perspective: Drug trends
Panel discussion from the 20th Annual Market Access Summit. As the COVID-19 pandemic continues to...
Article
Drug plans decoded: Biosimilars Part 4
Biosimilars in Canada: what plan sponsors can do. For plan sponsors that want to take advantage of...
Article
Drug plans decoded: Biosimilars Part 3
Public plans drive adoption of biosimilars So far, four provinces in Canada —British Columbia,...
Article
Drug plans decoded: Biosimilars Part 2
How Canada compares on biosimilars. Canada lags many countries when it comes to the uptake of...
Article
Drug plans decoded: Biosimilars Part 1
Biosimilars 101: what you need to know. Four provinces so far have implemented or are implementing...
Event and Webinar
Canadian drug landscape update: Spring 2021 webinar
With new COVID treatments on the horizon, a growing number of biosimilar options available, and...
Article
Estimating the financial impact of new medications for private drug plans
TELUS provides guidance on how to make a Budget Impact Analysis more relevant for private payers....
Article
2021 TELUS Health Drug Data Trends & National Benchmarks report
While COVID-19 clearly affected claims patterns for private drug plans in 2020, its net impact was,...